MOLOGEN AG: Updated data on renal cancer therapy MGN1601 with further improved results

• Median overall survival now over 16 months
• Presentation at the ESMO Meeting in Vienna

Berlin, October 1, 2012 – Updated data on the overall survival of patients participating in the ASET study was presented within the framework of a scientific poster at this year’s meeting of the European Society for Medical Oncology (ESMO). The clinical study with the renal cancer therapy MGN1601 has progressed further and now shows a median overall survival in the PP group of over 16 months.

MOLOGEN AG: Detailed study results on colorectal cancer therapy with MGN1703 presented at the ESMO meeting

Berlin, October 1, 2012 – At the meeting of the European Society for Medical Oncology (ESMO) detailed results for the colorectal cancer study with the DNA immunomodulator MGN1703 as maintenance therapy were presented today for the first time to an expert audience of clinical oncologists and cancer researchers. This immunomodulator MGN1703 is the first candidate of a whole new class of substances in colorectal cancer which could now be tested as efficacious in a randomized study.


About MOLOGEN AG
MOLOGEN AG, a German biopharmaceutical company with headquarters in Berlin specializes in the research and development of innovative medications on the basis of DNA structures. The activities focus on numerous product developments which are relevant to the immune system; on the one hand vaccines against infectious diseases and on the other hand cancer medications. MOLOGEN AG is globally one of the few biotechnology companies with well tolerated DNA-based cancer treatment in the clinical development phase.

The stocks of MOLOGEN AG (ISIN DE0006637200) are listed in the Prime Standard of the German stock exchange.

www.mologen.com


Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V. | DECHEMA - Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI)

MIDGE®, dSLIM® and MOLOGEN® are registered trademarks of MOLOGEN AG.


MOLOGEN AG

PRESS SERVICE:
Prof. Peter W. Huebner
Head of Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Tel: +49 - 30 - 84 17 88 - 50
huebner@mologen.com

INVESTOR RELATIONS:
Joerg Petrass
Tel: +49 - 30 - 84 17 88 - 13
Tel: +49 - 30 - 84 17 88 - 50
investor@mologen.com

External Investor Relations:
Kirchhoff Consult AG
Sebastian Bucher
T: +49 - 40 - 60 91 86 - 18
F: +49 - 40 - 60 91 86 -16
sebastian.bucher@kirchhoff.de

Note about risk for future predictions
Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.
 

Posted: October 2012

View comments

Hide
(web2)